Pharmacogenetics goes genomic

Nature Reviews Genetics

Volumn 4, Issue 12, 2003, Pages 937-947

  Goldstein, David B ^a   Tate, Sarah K ^a   Sisodiya, Sanjay M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELBAMATE; IMATINIB; IMIDAPRIL; ISONIAZID; MEPROBAMATE; MERCAPTOPURINE; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; PHENYTOIN; PRIMAQUINE; SUXAMETHONIUM; TRASTUZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ASTHMA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ECONOMIC ASPECT; ENTERITIS; FATALITY; GENETIC VARIABILITY; GENOME; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; LIVER FAILURE; LIVER METABOLISM; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL SPECIALIST; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHYSICIAN; POPULATION GENETICS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SAMPLE SIZE; SEIZURE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIETY; TOXICITY; TREATMENT PLANNING;

GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS;

GOES;

EID: 0345304425     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1229     Document Type: Review

References (54)

1. Weber, W. W. Pharmacogenetics (Oxford Univ. Press, New York and Oxford, 1997).
2. Motulsky, A. G. Drug reactions, enzymes, and biochemical genetics. J. Am. Med. Assoc. 165, 835-837 (1957). This paper was the first to make explicit the hypothesis that variation among individuals in drug response might be owing to subtle genetic differences with little or no obvious phenotypes except in response to the relevant drug. This perspective contributed directly to the development of pharmacogenetics as a distinct discipline.
3. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. & Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586 (1977).
4. Nebert, D. W. & Dieter, M. Z. The evolution of drug metabolism. Pharmacology 61, 124-135 (2000).
5. El-Bacha, R. S. & Minn, A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell. Mol. Biol. 45, 15-23 (1999).
6. Siddiqui, A. et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003). This paper reports the first polymorphism that was associated with the efficacy of anti-epileptic drugs and was one of the first pharmacogenetic studies to assess LD patterns around the associated variant and rule out population stratification.
7. Sisodiya, S. M. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16, 197-201 (2003).
8. Shah, R. R. The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54, 188-202 (2002).
9. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
10. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001)
11. Leabman, M. K. et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl Acad. Sci. USA 100, 5896-5901 (2003).
12. Fellay, J. et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36 (2002).
13. Gratze, G. et al. β-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33, 1425-1430 (1999).
14. Dishy, V. et al. The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035 (2001).
15. Drysdale, C. M. et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97, 10483-10488 (2000). This paper relates ADRB2 haplotypes to beta-agonist response in asthmatics and shows that haplotypes are a better predictor of response than individual SNPs.
16. Kaye, D. M. et al. β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13, 379-382 (2003).
17. Palmer, L. J., Silverman, E. S., Weiss, S. T. & Drazen, J. M. Pharmacogenetics of asthma. Am. J. Respir. Crit. Care Med. 165, 861-866 (2002).
18. Hirschhorn, J. N. Lohmueller, K., Byrne, E. & Hirschhorn, K. A comprehensive review of genetic association studies. Genet. Med. 4, 45-61 (2002).
19. Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S. & Hirschhorn, J. N. Meta-analysis of genetic association studies supports a contribution of common vanants to susceptibility to common disease. Nature Genet. 33, 177-182 (2003). This paper analyses 301 published studies covering 25 different reported associations for common disease. The analyses show that false-positive results cannot explain all of the associations.
20. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nature Rev. Cancer 2, 48-58 (2002).
21. Sham, P. C., Cherny, S. S., Purcell, S. & Hewitt, J. K. Power of linkage versus association analysis of quantitative traits, by use of variance-components models, for sibship data. Am. J. Hum. Genet. 66, 1616-1630 (2000).
22. Pritchard, J. K. & Rosenberg, N. A. Use of unlinked genetic markers to detect population stratification in association studies. Am J. Hum. Genet. 65, 220-228 (1999).
23. Reich, D. E. & Goldstein, D. B. Detecting association in a case-control study while correcting for population stratification. Genet. Epidemiol. 20, 4-16 (2001).
24. Kohlmeier, L., DeMarini, D. & Piegorsch, W. in Design Concepts in Nutritional Epidemiology (eds Margetts, B. & Nelson, M.) 312-337 (Oxford Univ. Press, Oxford, 1997).
25. Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892 (2002).
26. Peltonen, L. & McKusick, V. A. Genomics and medicine. Dissecting human disease in the postgenomic era, Science 291, 1224-1229 (2001).
27. Botstein, D. & Rfsch, N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nature Genet. 33 (Suppl.), 228-237 (2003)
28. Daly, M. J., Rioux, J. D., Schaffner, S. F., Hudson, T. J. & Lander, E. S. High-resolution haplotype structure in the human genome. Nature Genet. 29, 229-232 (2001). This paper introduces the idea of the human genome being partitioned into discrete haplotype blocks with limited diversity, which provided motivation for the HapMap project.
29. Johnson, G. C. et al. Haplotype tagging for the identification of common disease genes. Nature Genet. 29, 233-237 (2001).
30. Gabriel, S. B. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
31. Goldstein, D. B., Ahmadi, K. R., Weale, M. E. & Wood, N. W. Genome scans and candidate gene approaches in the study of common diseases and variable drug responses Trends Genet. 19, 615-622 (2003).
32. Holtzman, M. J. Drug development for asthma. Am. J. Respir. Cell Mol. Biol. 29, 163-171 (2003).
33. Goldstein, D. B. Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med. 348, 553-556 (2003).
34. Liggett, S. B. Polymorphisms of the β2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 156, 156-152 (1997). This paper introduces a model of receptor transport to explain responses to beta-agonists and shows the importance of combining functional and association data.
35. Noah, L. Author reply. N. Engl. J. Med. 348, 2041-2043 (2003).
36. Shah, J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nature Biotechnol. 217, 747-753 (2003).
37. Roses, A. D. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358-1361 (2000)
38. Xie, H. G., Kim, R. B., Wood, A. J. & Stein, C. M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
39. Carmena, R., Roederer, G., Mailloux, H., Lussier-Cacan, S. & Davignon, J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42, 895-901 (1993).
40. Ojala, J. P. et al. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J. Intern. Med. 230, 397-405 (1991).
41. Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993).
42. Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977-1981 (1993)
43. Roses, A. D. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541-549 (2002). This paper describes the use of a candidate-gene approach to identify variants for rare adverse drug reactions (abacavir hypersensitivity).
44. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. & Lasagna, L. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107-142 (1991).
45. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. & Lasagna, L. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics 7, 152-169 (1995).
46. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
47. Mancinelli, L., Cronin, M. & Sadee, W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci. 2, 4 (2002).
48. Seidman, E. G. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev. Gastroenterol. Disord. 3 (Suppl.), 30-38 (2003).
49. Marra, C. A., Esdaile, J. M. & Anis, A. H. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29, 2507-2512 (2002).
50. McLeod, H. L. & Siva, C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3, 89-98 (2002).
51. van Aken, J., Schmedders, M., Feuerstein, G. & Kollek, R. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics 3, 149-155 (2003).
52. Pellock, J. M. Felbamate. Epilepsia 40 (Suppl.), 57-62 (1999)
53. Kapetanovic, I. M. et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem. Biol. Interact. 142, 119-134 (2002).
54. Roller, S. G. et al. Interaction between human serum albumin and the felbamate metabolites 4-hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. Chem. Res. Toxicol. 15, 815-824 (2002).